<p>|Recommendations|Level of evidence (evidence [refs.] reviewed)†|
|---|---|
|In OSM- and other treatment–naive patients with active PsA,| |
|1. Treat with a TNFi biologic over an OSM (MTX, SSZ, LEF, CSA, or APR) (PICO 10a–e)|Low (53–66)|